Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop.

The GoFundMe page was set up to raise money to cover the cost of life-saving treatment for the 14-year-old boys, who suffer ...

JMP Securities reiterated their Market Outperform rating on Solid Biosciences (NASDAQ:SLDB) with a steady price target of $15.00. Currently trading at $3.04, the company has a market capitalization of ...

Entrada plans to initiate clinical testing of ENTR-601-44 in Duchenne MD patients amenable to exon 44 skipping later this year.

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

Weight-loss medication has taken the world by storm and helped many overweight people. But for some, significant weight loss ...

Evan McMenamin said his brother Travis, "never lets it get him down" despite the "incredible challenges" he faces ...

This influx of calcium at the contact site attracts and activates a kinase called CaMKII, a protein known to be important in ...

Following his diagnosis with the inherited condition, which causes progressive muscle weakness, in November 2016, 12-year-old Alfie has been attending bi-annual appointments at a private hospital in ...

New research shows that a network of subcellular structures similar to those responsible for propagating molecular signals that make muscles contract are also responsible for transmitting signals in ...